MPU
OPTN

MVM Partners (UK)’s OptiNose OPTN Stock Holding History

MVM Partners (UK)’s Portfolio OPTN Stock Details OPTN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-833,333
Closed -$45.5M – 3
2022
Q2 		$45.5M Hold
833,333
– – 16.06% 2
2022
Q1 		$30.6M Hold
833,333
– – 10.92% 2
2021
Q4 		$20M Buy
+833,333
New +$27.9M 7.13% 2

Other funds holding OPTN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
EIP
Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

MVM Partners (UK)'s OPTN Position: Q3 2022 in Review

MVM Partners (UK) sold out of OptiNose (OPTN) in Q3 2022, closing a stake of 833,333 shares — an estimated $45.5M sold.

MVM Partners (UK) first reported a position in OPTN in Q4 2021 and held it in 3 quarters. The position peaked at $45.5M in Q2 2022. 50 funds tracked by Wall St. Rank hold OPTN as of Q3 2022.

  • MVM Partners (UK) reported no remaining OptiNose position as of Q3 2022 after selling out during the quarter.
  • MVM Partners (UK) sold 833,333 OptiNose shares in Q3 2022, an estimated $45.5M.
  • MVM Partners (UK) first reported a position in OptiNose in Q4 2021 and held it in 3 quarters.
  • MVM Partners (UK)'s OptiNose position peaked at $45.5M in Q2 2022.
  • 50 funds tracked by Wall St. Rank held OptiNose as of Q3 2022.

Based on MVM Partners (UK)'s 13F filing for Q3 2022, filed 25 Oct 2024.